Skip to main content

Table 3 Characteristics of HSCT recipients

From: Gastrointestinal peptides in children before and after hematopoietic stem cell transplantation

Number of patients

27

Sex

boys-20, girls-7

Age (years)

1.5–19 (mean 9, median 9.6)

Neoplastic diseases, n (n %)

18 (67%)

Chemotherapy before HSCT, n (n %)

17 (63%)

Local radiotherapy

5 (CNS-4,Testes-1)

Time since diagnosis (years)

 Neoplastic diseases

Median-1, mean-2; range 0.1–7

 Non-neoplastic diseases

Median-1.5, mean-3.8, range 0.1–13

Conditioning regimen based on busulfan or treosulfan, n (n %)

16(60%)

Total body irradiation – 12Gy/6fractions, n (n %)

7 (26%)

GvHD prophylaxis, n (n %)

 CSA

4 (15%)

 MTX + CSA

23 (85%)

Mucositis, n (%)

22 (82%)

 Grade, n

I-7, II-8, III-6, IV-1

Intravenous alimentation due to mucositis (%)

48

aGvHD, n (n %)

11 (41)

 Localisation, %

Gut-9, Skin-91, Liver-27

 Grade, n

IA-1, IB-4, IIB-1, IIC-3, IIIC-2

Systemic glucocorticoid treatment, n (%)

19 (70)

Systemic glucocorticoid treatment (days)

Median-3.5, mean-3.6; range 0.1–11

Time from discontinuation of systemic glucocorticoids to the second assessment (months)

Median-3.6, mean-4.5; range 0.5–14

Time from discontinuation of immunosuppressive treatment to the second assessment (months)

Median 1.6; range 0–9

Time from HSCT to the second assessment (months)

Median 6.3 (5.9–19.1)

  1. aGvHD acute graft-versus-host disease, CSA cyclosporin, MTX methotrexate